ProMIS Neurosciences, Inc. (PMN.TO)
| Previous Close | 7.90 |
| Open | 7.80 |
| Bid | 7.90 x 0 |
| Ask | 8.10 x 0 |
| Day's Range | 7.61 - 7.90 |
| 52 Week Range | 6.00 - 12.22 |
| Volume | |
| Avg. Volume | 1,451 |
| Market Cap | 3.411B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | Nov 10, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.50 |
- GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights
Closed US$7.4 million private placementAppointed Gail Farfel, Ph.D., as Chief Executive OfficerContinued progress toward investigational new drug (IND) submission for PMN310 to pursue Alzheimer’s disease indication TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the developme
- GlobeNewswire
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement
Toronto, Ontario and Cambridge, MA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Uni
- GlobeNewswire
ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
New CEO brings 25 years’ experience and successful track record in neurological and neuropsychiatric drug developmentTORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail
